May 2026
đź“Ł VC round data is live. Check it out!
Largest Biopharmaceuticals Public Companies in South Korea
Benchmark revenue and EBITDA valuation multiples for public comps like
Celltrion, Alteogen, Samsung Bioepis, Samchundang Pharm and SK Biopharmaceuticals.
 | Celltrion Inc is a biopharmaceutical company that focuses on the research, development, and manufacture of biosimilars and novel biopharmaceuticals. The company's operating segments include Biopharmaceuticals and Chemical medicine segment. Its Biopharmaceuticals segment includes products and commodities such as biopharmaceutical drugs and related product-support services. The Chemical Medicine segment covers products and commodities including various chemical medicines. It generates the majority of its revenue from the Biopharmaceuticals segment. | $131 | +24% | $29B | $30B | 10.7x | 29.7x | ||
| Alteogen Inc Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion Technology. It also develops & markets biobetters and biosimilars through partnerships with pharmaceutical companies. It focuses on areas such as biobetters, a proprietary antibody-drug conjugate, and antibody biosimilars with complexity. | $241 | +8% | $13B | $13B | 88.4x | 106.4x | ||
| Samsung Epis Holdings Co Ltd is engaged in managing and making new investments in the biopharmaceutical sector. | $331 | -- | $8B | $8B | — | — | ||
| Samchundang Pharm Co Ltd is engaged in manufacturing, distributing, importing, and exporting pharmaceuticals in South Korea. The company offers ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as gastro intestines and vitamins. | $246 | +149% | $6B | $6B | 37.1x | 350.9x | ||
| SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in the research and development of new drugs for the treatment of central nervous system (CNS) disorders. The company is also researching the development of drugs to treat brain tumors, including metastatic tumors. Its drug pipeline includes Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and more. | $65 | +3% | $5B | $5B | 10.2x | 33.3x | ||
| ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody. | $79 | +48% | $4B | $4B | 75.7x | (194.2x) | ||
| Yuhan Corp is a pharmaceutical company. The core business of the company is classified as primary and specialty care, dietary supplements, household and animal care, and contract manufacturing of active pharmaceutical ingredients. The company offers one-stop custom synthesis services from research and development to commercial production of active pharmaceutical products (APIs) and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets. | $58 | -17% | $4B | $4B | 2.9x | 21.3x | ||
| Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group’s research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson’s and Alzheimer’s disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor. | $170 | +8% | $4B | $4B | 1044.3x | (571.8x) | ||
| Hanmi Pharm Co Ltd is a Korea-based company, engaged in manufacturing and marketing of medicines, medical supplies and raw materials for medicines. The company makes strenuous and enthusiastic efforts to develop treatments for diabetes, obesity, cancer, autoimmune and rare disease to keep everyone's health and improve their quality of life. The group distributes its products within Korean market and to overseas markets. | $300 | +43% | $4B | $4B | 3.8x | 16.4x | ||
| LigaChem Biosciences Inc develops new drugs through research. The Company provides business research services, manufacturing and sale of compounds, and drug evaluation. | $104 | +34% | $4B | $3B | 37.1x | (60.9x) | ||
| Voronoi Inc is a biotech company that develops novel kinase inhibitors and targets protein degraders. It is principally focused on developing targeted therapies for anticancer drugs such as lung and breast cancer. Its pipeline products are: VRN11, VRN16, VRN10, VRN19, VRN07, VRN04, VRN06, and others. | $186 | +161% | $3B | $3B | 614.8x | (107.3x) | ||
| SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and development of vaccines. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further, it has several other vaccines under development and clinical trials, including a recombinant rotavirus vaccine. | $28 | -7% | $2B | $2B | 4.3x | 200.8x | ||
| D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations. | $46 | +216% | $2B | $2B | 248.6x | (159.1x) | ||
| Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology. | $38 | +116% | $2B | $2B | 18.2x | 556.5x | ||
| Hugel Inc is a biopharmaceutical company. It is in the business of manufacturing of biopharmaceuticals. The company's primary products are Botulinum toxin, Hyaluronic acid filler, and Cosmetics. It develops and promotes its products under the brand name of Wellage. The firm has manufacturing facilities in Shinbuk and Geodu. | $177 | -21% | $2B | $2B | 5.3x | 10.2x | ||
| Celltrion Pharm Inc is active in the Korean healthcare sector. Its core business includes the manufacture and sale of pharmaceuticals such as heptatonic, analgesics, antipyretics, anti-inflammatory drugs, antihistamines, respiratory apparatus drugs and antibiotics. | $34 | +4% | $1B | $2B | 4.3x | 29.4x | ||
| Mezzion Pharma Co is a South Korea based drug manufacturer company. It develops and manufactures pharmaceutical products for erectile dysfunction and benign prostatic hyperplasia. | $49 | -- | $1B | $1B | 258.5x | (167.7x) | ||
| Oscotec Inc is engaged in drug discovery for osteoporosis, arthritis, periodontal, dental health and cancer diseases. | $28 | +41% | $1B | $975M | 14.6x | 26.0x | ||
| Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam. | $90 | -16% | $1B | $1B | 1.4x | 8.7x | ||
| HK Inno N Corp manufactures pharmaceutical products. | $31 | +11% | $881M | $1B | 1.5x | 10.5x | ||
| Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand. | $9 | +139% | $854M | $839M | 360.9x | (69.1x) | ||
| AprilBio Co Ltd is a bio company is developing biologis. It owns long acting protein medicine platform technology utilizing human FAB antobody parts that makes unusual combination to serum akbumin and EX 12 helper phase antibody library technology. | $37 | +225% | $836M | $775M | 110.3x | 463.2x | ||
| Chabiotech Co Ltd is engaged in the manufacturing of biological products. | $9 | +34% | $716M | $1B | 1.3x | (51.4x) | ||
| Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent). | $53 | -9% | $697M | $711M | 0.6x | 8.1x | ||
| Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia. | $11 | +39% | $659M | $633M | 8.2x | 24.7x | ||
| Onconic Therapeutics Inc is a company that researches and develops new drugs for gastrointestinal diseases and anticancers, which have large unmet medical needs. Its pipeline products are Zataprazan(OCN-101) and OCN-201. | $14 | +276% | $614M | $576M | 16.3x | 61.1x | ||
| Abclon Inc is engaged in the research and development of antibody drugs. Its business sector is divided into Antibody drug and Bio CRO. | $27 | +203% | $512M | $489M | 156.9x | (45.3x) | ||
| Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others. | $68 | -41% | $445M | $464M | 2.8x | 25.0x | ||
| Dong-A Socio Holdings Co Ltd is a pharmaceutical company. The company is engaged in the development of biomedicines and innovative drugs, and to expand businesses from pharmaceuticals to medical services and new businesses. | $61 | -- | $406M | $717M | 0.7x | 6.1x | ||
| IMBiologics Corp is a next-generation biopharmaceutical company developing antibody therapeutics. Its proprietary IM-OpDECon platform enables the design of differentiated biologics targeting autoimmune diseases and immuno-oncology. The group leverages diverse antibody modalities to tackle critical unmet medical needs beyond the reach of current therapies. Its business areas are Antibody Research & Development and Autoimmune Diseases Immuno-Oncology. The group's pipeline products are IMB-101/102, IMB-201, and IMB-402. | $25 | -- | $371M | $371M | — | — | ||
| Medipost Co Ltd is a Korea-based stem cell biotechnology company. The company is engaged in developing products to meet unmet medical needs. The company operates its business through four distinct segments: Stem Cell Therapeutics, Cord Blood Bank, Cosmetics, and Health Supplements. The Cord Blood Bank Division is involved in collecting and storing stem cells from the newborn's umbilical cord. The Stem Cell Therapeutics division manufactures allogeneic stem cell drug products. The Health Supplements division offers vitamins and nutritional supplements. The Cosmetics division is involved in the sales and marketing of natural cosmetics. | $9 | -- | $347M | $323M | 6.6x | (6.2x) | ||
| Huons Co Ltd is a Korean company. It is engaged in the manufacture and distribution of pharmaceutical products. The company produces pharmaceutical products including parenteral injections such as lidocaines, merit C injections; tablets such as phentermine, diet pills, and capsules such as Daisen and Fuxetine and other ethical and over-the-counter drugs. It also produces ampoules, vials, cartridges, and caps for use of medicals, foods, and cosmetics. | $23 | -- | $273M | $348M | 0.8x | 6.4x | ||
| S Biomedics Co Ltd is engaged in development, manufacturing and supply of stem cell treatment products, and main business is the production and sale of pharmaceutical products. | $23 | +77% | $269M | $269M | 24.6x | (122.6x) | ||
| Dong-A ST Co Ltd is a Korea-based company principally engaged in the manufacturing and distribution of specialty pharmaceuticals. The company also involves in the provision of medical devices, diagnostic detection, as well as overseas sale business. Its in-house developed original drugs are used for gastritis treatment, erectile dysfunction treatment, functional dyspepsia, oxazolidinone class antibiotic, and diabetes treatment. | $28 | -- | $267M | $441M | 0.8x | 11.6x | ||
| Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others. | $32 | +14% | $260M | $241M | 21.9x | 634.2x | ||
| Kanaph Therapeutics Inc is a biotech company dedicated to developing anticancer drugs and ophthalmic disease treatments based on human genome-based drug development technology. Its core technology lies in identifying novel targets with high unmet medical needs through the analysis of human genome data and disease-specific biological signatures, and in developing drugs of various modalities, including bispecific antibodies, antibody-drug conjugates (ADCs), and synthetic drugs, based on these findings. The groups pipeline products are KNP-101, KNP-301, KNP-502, KNP-503, KNP-504, and KNP-701. | $19 | -- | $243M | $211M | 54.2x | (10.4x) | ||
| Binex Co Ltd is engaged in manufacturing and distribution of pharmaceutical products. The key products include gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as an ointment, creams, and others. It also manufactures biomedicines and raw materials. Its other business operation involved contract development and manufacturing business for other companies. The company invests in some bio ventures that develop biomedicines. | $6 | -43% | $207M | $258M | 2.3x | 30.9x | ||
| Prestige Biologics Co Ltd is a CDMO-dedicated company that provides solutions of development and manufacturing tasks throughout the stages from the research/development, engineering, clinical production, commercial production, clinical support, and IND & BLA filing of biopharmaceutical products. Its product candidate includes HD201 (Herceptin Biosimilar). | $1 | -48% | $105M | $160M | 19.3x | (42.8x) | ||
| Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis. | $8 | -- | $101M | $88M | 5329.3x | (35.5x) | ||
| Vaxcell-Bio Therapeutics is a bio-technology company engaged in the development of Cell-based and Protein-based Immunotherapeutics for the treatment of cancer. | $4 | -34% | $99M | $83M | 17.9x | (11.5x) | ||
| Dongkoo Bio&Pharma Co Ltd is engaged in the research, development, manufacture, and sale of pharmaceuticals products. The company provides products for digestants, other analgesics and antipyretics, nonsteroidal anti-inflammatory drugs, oral hypoglycemic agents, antiplatelet agents, antihistamines and anti-allergic, and decongestants and nasal sprays. It offers its products in multiple forms such as capsules, tablet, powder, granule, and liquid. The company exports its products to various countries including Vietnam, New Zealand, Thailand, Hong Kong and Singapore. | $3 | -- | $85M | $147M | 0.9x | 3.0x | ||
| Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease. | $2 | +37% | $70M | $90M | 6.7x | (6.5x) | ||
| HLB Global Co Ltd is engaged in multiple businesses including Sea mining, Fermented beverage production and sales, Biopharmaceutical development, and Eco-friendly Green Wall Creation Project. | Alcohol+1 | $1 | -- | $61M | $69M | 1.0x | 31.9x | |
| Oncocross Co Ltd is innovating the drug development process through its AI approach for developing treatments for cancers, rare diseases, and intractable diseases, thereby contributing to a healthier world. Its Technology platforms include ONCOCROSS AI Platform, RAPTOR AI, ONCO-RAPTOR AI, and ONCOfind AI. | $5 | -50% | $57M | $45M | 185.1x | (9.0x) | ||
| SyntekaBio Inc is a bioinformatics venture firm. It is engaged in gene-related research, technology development, and genetic analysis based on the genome big data platform and artificial intelligence deep learning drug development platform. The company manages and analyzes genome analysis and massive biodata and genome. | $2 | -60% | $30M | $24M | 10.6x | (2.9x) | ||
| Median | $31 | +19% | $716M | $775M | 10.7x | 8.1x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.